SA PRO
Free Account
Immunovant, Inc.IMVTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 78% recommend buying.

Consensus Rating
Buy
23 analysts·High coverage
78%
Rating Distribution
Strong Buy
00%
Buy
1878%
Hold
417%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 36% higher.

Bear Case
$16.00
-39%
Consensus
$35.67
+36%
Bull Case
$50.00
+91%
Price Range23 analysts
Low
Consensus
High
$16.00
$50.00
Current Target
Current Price
$26.14
Upside to Target
$9.53

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 6, 2026Wolfe Research
Immunovant upgraded to Outperform at Wolfe on improving Graves' perception
Target:$50.00
+100.2%from $24.97
Dec 18, 2025Guggenheim
Immunovant price target lowered to $41 from $44 at Guggenheim
Target:$41.00
+56.1%from $26.27
Oct 14, 2025Truist Financial
Immunovant initiated with a Hold at Truist
Target:$16.00
-7.8%from $17.35
Sep 10, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)
Target:$51.00
+68.9%from $30.20
Jun 3, 2024Oppenheimer
Immunovant price target lowered to $46 from $50 at Oppenheimer
Target:$46.00
+81.2%from $25.39
May 30, 2024Guggenheim
Immunovant (IMVT) PT Lowered to $48 at Guggenheim
Target:$48.00
+81.7%from $26.41
May 30, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
Target:$57.00
+104.8%from $27.83
Mar 13, 2024Goldman Sachs
Goldman Sachs Starts Immunovant (IMVT) at Buy
Target:$50.00
+57.1%from $31.82
Sep 26, 2022UBS
Immunovant downgraded to Neutral from Buy at UBS
Target:$5.00
+2.5%from $4.88

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance